Novocure Deutschland – Pioneer in innovative cancer therapy. The global oncology company extends survival in aggressive cancers with the groundbreaking TTFields therapy. Become part of our team! #Krebstherapie #Innovation
Sign up for free.
Novocure is a global oncology company that extends survival in aggressive cancers with the groundbreaking Tumor Treating Fields (TTFields) therapy. Worldwide, over 30,000 patients have already been treated with this non-invasive method, which uses electrical fields to disrupt the division of cancer cells.[1][3]
The core of Novocure is the TTFields therapy, a portable, at-home treatment. In Germany, it is approved as a benefit of statutory health insurance for newly diagnosed Glioblastoma (GBM), one of the most aggressive brain tumors. The systems are also CE-certified for recurrent Glioblastoma and Pleuramesothelioma, a rare cancer of the lining of the lungs.[2] Devices like Optune® enable continuous therapy that patients can integrate into their daily lives – as patient reports in videos show, in which those affected share their positive experiences.[7]
The therapy is based on the discovery of the founder Prof. Yoram Palti in 2000: TTFields exploit the electrical properties of dividing tumor cells to inhibit their growth without severely affecting healthy cells.[3] Novocure distributes and markets these medical devices and acts as an authorized representative in Europe.[4]
Together with patients, we strive to extend survival in some of the most aggressive forms of cancer – that is the central mission.[1][3] Novocure focuses on innovation, patient proximity, and evidence-based medicine. Milestones such as the positive results of the EF-14 Phase III study form the basis for success and have established TTFields.[1] In Germany, based in Munich since 2017, the team around Dr. med. Adrian Kinzel (Vice President Germany since 2025) and Dr. med. Sandra Ehrle (Head of Medical Affairs) optimally supports practitioners and patients.[1]
The company is involved in politics and society, e.g. in the lobby register for topics such as healthcare, research and industrial policy, to ensure access to therapy.[2] Employee reviews highlight a strong working atmosphere (4.7/5), collegial cohesion (4.7/5) and equality (4.8/5), which underscores the value-oriented culture.[6]
Novocure is conducting intensive research worldwide in preclinical and clinical studies on TTFields in other solid tumors, with promising results.[2][3] Global sales of TTFields rose to USD 605 million in 2024, with Germany being a key market with USD 65 million.[5] The company aims to make the therapy accessible to more patients and to develop new indications.[8]
Although explicit sustainability goals are not highlighted in detail, the high employee satisfaction with environmental/social awareness (4.1/5) reflects responsible action.[6] Novocure embodies hope for cancer patients: A therapy that extends life and increases quality.
(Total length: approx. 2480 characters incl. spaces)
